Cytokinetics Stock Financials

CYTK
 Stock
  

USD 41.00  2.90  6.61%   

Cytokinetics Invested Capital is increasing as compared to previous years. The last year's value of Invested Capital was reported at 926.72 Million. The current Invested Capital Average is estimated to increase to about 879.1 M, while Earnings before Tax are projected to decrease to (221 M).
  
Refresh
With this module, you can analyze Cytokinetics financials for your investing period. You should be able to track the changes in Cytokinetics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Cytokinetics Most Recent Estimates

EPS Estimate Next Quarter
-1.0
Diluted Eps
-3.21
EPS Estimate Current Year
-4.38
EPS Estimate Next Year
-4.28
EPS Estimate Current Quarter
-0.94
Earnings Share
-3.21

Revenues

59.29 Million

Understanding current and past Cytokinetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cytokinetics' financial statements are interrelated, with each one affecting the others. For example, an increase in Cytokinetics' assets may result in an increase in income on the income statement.
The fundamental analysis of Cytokinetics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Cytokinetics includes many different criteria found on its balance sheet. For example, investors should never minimize Cytokinetics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Cytokinetics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Cytokinetics.

Cytokinetics Cash

Chance Of Financial Distress
Over 90
Cytokinetics has more than 90 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Cytokinetics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Cytokinetics' official financial statements usually reflect Cytokinetics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cytokinetics. For example, before you start analyzing numbers published by Cytokinetics accountants, it's critical to develop an understanding of what Cytokinetics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Cytokinetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cytokinetics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cytokinetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cytokinetics. Please utilize our Beneish M Score to check the likelihood of Cytokinetics' management to manipulate its earnings.

Cytokinetics Company Summary

Cytokinetics competes with Omnia Wellness. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001061983
CUSIP23282W100
RegionNorth America
LocationCalifornia; U.S.A
Business Address350 Oyster Point
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.cytokinetics.com
Phone650 624 3000
CurrencyUSD - US Dollar
You should never invest in Cytokinetics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cytokinetics Stock, because this is throwing your money away. Analyzing the key information contained in Cytokinetics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Cytokinetics Key Financial Ratios

Generally speaking, Cytokinetics' financial ratios allow both analysts and investors to convert raw data from Cytokinetics' financial statements into concise, actionable information that can be used to evaluate the performance of Cytokinetics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cytokinetics reports annually and quarterly.

Cytokinetics Key Balance Sheet Accounts

201720182019202020212022 (projected)
Accounts Payable5.25 M3.76 M8.16 M8.05 M21.09 M22.75 M
Total Assets294.81 M211.18 M289.81 M533.8 M841.32 M907.74 M
Current Assets274.3 M207.67 M233.75 M474.22 M535.67 M577.96 M
Assets Non Current20.52 M3.5 M56.06 M59.58 M305.65 M329.78 M
Cash and Equivalents125.21 M42.26 M36.43 M82.98 M112.67 M91.18 M
Total Debt31.78 M43.18 M136.07 M138.94 M269.93 M291.24 M
Debt Non Current31.78 M40.58 M131.45 M136.15 M255.07 M275.2 M
Deferred Revenue20.86 M23.06 M24.57 M87 M100.05 M107.95 M
Shareholders Equity109.84 M25.93 M(10.94 M)113.38 M243.86 M263.12 M
Investments160.2 M156.47 M231.33 M418.03 M511.02 M551.37 M
Investments Current143.69 M156.47 M188.68 M381.07 M358.97 M387.31 M
Total Liabilities184.97 M185.24 M300.75 M420.42 M597.46 M644.62 M
Current Liabilities32.44 M22.19 M26.02 M31.2 M71.86 M77.53 M

Cytokinetics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Cytokinetics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Gross Profit13.37 M31.5 M26.87 M55.83 M70.43 M59.29 M
Interest Expense3.02 M3.8 M6.62 M15.96 M16.44 M17.74 M
Net Income(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Operating Expenses126.76 M120.42 M125.73 M149.77 M256.74 M277.01 M
Operating Income(113.4 M)(88.92 M)(98.87 M)(93.94 M)(186.31 M)(191.22 M)
Revenues13.37 M31.5 M26.87 M55.83 M70.43 M59.29 M

Cytokinetics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Cytokinetics. It measures of how well Cytokinetics is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Cytokinetics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Cytokinetics had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Cytokinetics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(2.88 M)(875 K)(2.62 M)(11.05 M)(48.87 M)(50.16 M)
Depreciation Amortization and Accretion1.92 M1.24 M1.29 M1.83 M2.28 M1.87 M
Net Cash Flow or Change in Cash and Cash Equivalents58.33 M(82.95 M)(5.82 M)46.55 M29.68 M32.02 M
Issuance Purchase of Equity Shares134.04 M3.23 M37.61 M231.97 M319.98 M345.24 M
Issuance Repayment of Debt Securities15 M1.26 M9.9 M122.18 M140.51 M151.6 M
Net Cash Flow from Financing225.92 M13.13 M159.79 M234.12 M319.98 M345.24 M
Net Cash Flow from Investing(65.83 M)5.13 M(74.71 M)(196.51 M)(147.78 M)(151.67 M)
Net Cash Flow Investment Acquisitions and Disposals(62.95 M)6.01 M(72.09 M)(185.46 M)(98.91 M)(101.51 M)
Net Cash Flow from Operations(101.76 M)(101.22 M)(90.91 M)8.94 M(142.52 M)(146.27 M)
Share Based Compensation9.03 M9.76 M10.76 M17.62 M26.83 M28.95 M

Cytokinetics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cytokinetics's current stock value. Our valuation model uses many indicators to compare Cytokinetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cytokinetics competition to find correlations between indicators driving Cytokinetics's intrinsic value. More Info.
Cytokinetics is number one stock in operating margin category among related companies. It is number one stock in shares owned by institutions category among related companies . Cytokinetics Operating Margin is increasing as compared to previous years. The last year's value of Operating Margin was reported at 15.81. Comparative valuation analysis is a catch-all model that can be used if you cannot value Cytokinetics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cytokinetics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cytokinetics' earnings, one of the primary drivers of an investment's value.

Cytokinetics Systematic Risk

Cytokinetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cytokinetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-five with a total number of output elements of thirty-six. The Beta measures systematic risk based on how returns on Cytokinetics correlated with the market. If Beta is less than 0 Cytokinetics generally moves in the opposite direction as compared to the market. If Cytokinetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cytokinetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cytokinetics is generally in the same direction as the market. If Beta > 1 Cytokinetics moves generally in the same direction as, but more than the movement of the benchmark.
.

About Cytokinetics Financials

What exactly are Cytokinetics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Cytokinetics' income statement, its balance sheet, and the statement of cash flows. Potential Cytokinetics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Cytokinetics investors may use each financial statement separately, they are all related. The changes in Cytokinetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytokinetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Cytokinetics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Cytokinetics grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Cytokinetics July 6, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Cytokinetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cytokinetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cytokinetics based on widely used predictive technical indicators. In general, we focus on analyzing Cytokinetics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cytokinetics's daily price indicators and compare them against related drivers.
Downside Deviation5.68
Information Ratio0.1182
Maximum Drawdown30.91
Value At Risk(8.11)
Potential Upside8.35
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.5 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.